Astellas Pharma, Apr-Jun (1Q) Net Income Increases by 82%

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Wed Jul 30, 2025 3:30 pm JST Earnings

4503 Astellas Pharma Inc. 【IFRS】

Earnings Report

Astellas Pharma Inc. <4503> [TSE Prime] announced its financial results (based on IFRS) after the market closed on July 30th (15:30). The consolidated net income for the first quarter of the fiscal year ending March 2026 (April to June) expanded 68.4 billion yen, an increase 82.0% compared to the same period last year. Progress toward the full-year plan of 130 billion yen was 52.6%, it was below the five-year average of 72.0%.

In the most recent three-month period, from April to June (1Q), the operating profit margin jumped from 10.7% in the same period last year to 18.7%.

Kabutan News

Actual Results

Accumulated Results 1st Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Jun, 2023	374,990	45,794	46,850	33,129	18.5	83.2	Aug 1, 2023	IFRS
Apr - Jun, 2024	473,124	50,657	50,495	37,603	21.0	56.7	Aug 1, 2024	IFRS
Apr - Jun, 2025	505,794	94,647	90,416	68,422	38.2	ー	Jul 30, 2025	IFRS
YoY	+6.9%	+86.8%	+79.1%	+82.0%	+82.0%

Current Period Guidance

H1 Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Apr - Sep, 2024	935,621	93,710	89,042	73,511	41.1	37	Oct 30, 2024	IFRS
Apr - Sep, 2025 Guidance	ー	ー	ー	ー	－	39	Apr 25, 2025	IFRS
YoY	－	－	－	－	－

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2024	1,603,672	25,518	24,969	17,045	9.5	70	Apr 25, 2024	IFRS
Mar, 2025	1,912,323	41,039	31,237	50,747	28.4	74	Apr 25, 2025	IFRS
Mar, 2026 Guidance	1,930,000	160,000	150,000	130,000	72.6	78	Apr 25, 2025	IFRS
YoY	+0.9%	+289.9%	+380.2%	+156.2%	+156.0%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Apr - Jun, 2024	473,124	50,657	50,495	37,603	21.0	10.7	Aug 1, 2024	IFRS
Jul - Sep, 2024	462,497	43,053	38,547	35,908	20.1	9.3	Oct 30, 2024	IFRS
Oct - Dec, 2024	517,408	-116,191	-118,359	-97,660	-54.6	-22.5	Feb 4, 2025	IFRS
Jan - Mar, 2025	459,294	63,520	60,554	74,896	41.8	13.8	Apr 25, 2025	IFRS
Apr - Jun, 2025	505,794	94,647	90,416	68,422	38.2	18.7	Jul 30, 2025	IFRS
YoY	+6.9%	+86.8%	+79.1%	+82.0%	+82.0%